$SNTI
Senti Biosciences, Inc. Stock $snti

$snti Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000185427022000019 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$1.766M	$1.358M	$0.00
YoY Change		71.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.80M	$13.88M	$50.27K
YoY Change	26114.18%	25523.04%	-98.83%
% of Gross Profit
Research & Development	$8.056M	$9.247M	$7.603M
YoY Change	48.91%	76.64%	55.16%
% of Gross Profit
Depreciation & Amortization	$400.0K	$300.0K	$200.0K
YoY Change	100.0%	50.0%	17.65%
% of Gross Profit
Operating Expenses	$18.85M	$23.13M	$1.333M
YoY Change	6297.98%	136.28%	112866.95%
Operating Profit	-$17.09M	-$21.77M	-$11.76M
YoY Change	49.57%	142.01%
Interest Expense	$542.0K	$27.00K	$23.16K
YoY Change	18210.81%	1250.0%
% of Operating Profit
Other Income/Expense, Net	$445.0K	$10.22M	-$50.00K
YoY Change	2517.65%	-439.39%	-99.58%
Pretax Income	-$16.64M	-$11.55M	-$1.310M
YoY Change	5604.88%	5504.89%	110904.24%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$16.64M	-$11.55M	-$11.81M
YoY Change	5604.88%	-3.79%	-43.78%
Net Earnings / Revenue	-942.24%	-850.66%
Basic Earnings Per Share	-$0.38	-$0.86	-$3.72
Diluted Earnings Per Share	-$0.38	-$0.86	-$44.45K
COMMON SHARES
Basic Shares Outstanding	43.39M shares	13.45M shares	3.171M shares
Diluted Shares Outstanding	43.42M shares	13.45M shares	3.171M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$114.9M	$139.8M	$396.7K
YoY Change	11574.49%	12645.01%
Cash & Equivalents	$114.9M	$139.8M	$38.14M
Short-Term Investments
Other Short-Term Assets	$56.00K	$28.00K	$430.5K
YoY Change	-91.68%	-96.44%
Inventory
Prepaid Expenses	$2.277M	$2.535M
Receivables	$846.0K	$600.0K	$400.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$119.8M	$143.9M	$827.2K
YoY Change	7125.09%	7537.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$47.26M	$35.51M	$44.20M
YoY Change	77.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$243.0K	$207.0K	$230.1M
YoY Change	-99.89%	-99.91%	61477.02%
Total Long-Term Assets	$69.68M	$58.44M	$230.1M
YoY Change	-69.7%	-74.59%
TOTAL ASSETS
Total Short-Term Assets	$119.8M	$143.9M	$827.2K
Total Long-Term Assets	$69.68M	$58.44M	$230.1M
Total Assets	$189.4M	$202.4M	$230.9M
YoY Change	-18.23%	-12.73%	61698.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.768M	$5.755M	$32.86K
YoY Change	1964344.44%	127505.32%	117257.14%
Accrued Expenses	$13.84M	$10.90M	$4.018M
YoY Change	10644.8%	19188.62%	401737.0%
Deferred Revenue	$99.00K	$833.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.84M	$17.80M	$4.051M
YoY Change	12191.04%	29062.71%	1058.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$33.26M	$30.30M	$7.050M
YoY Change	313.18%	276.4%
Total Long-Term Liabilities	$33.26M	$30.30M	$7.050M
YoY Change	313.18%	276.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.84M	$17.80M	$4.051M
Total Long-Term Liabilities	$33.26M	$30.30M	$7.050M
Total Liabilities	$49.10M	$48.10M	$11.10M
YoY Change	500.3%	492.97%	3073.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$155.1M	-$138.4M
YoY Change
Common Stock	$4.000K	$4.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$140.3M	$154.3M	-$121.8M
YoY Change
Total Liabilities & Shareholders Equity	$189.4M	$202.4M	$230.9M
YoY Change	-18.23%	-12.73%	61698.89%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$16.64M	-$11.55M	-$11.81M
YoY Change	5604.88%	-3.79%	-43.78%
Depreciation, Depletion And Amortization	$400.0K	$300.0K	$200.0K
YoY Change	100.0%	50.0%	17.65%
Cash From Operating Activities	-$25.40M	-$5.690M	-$492.6K
YoY Change	22505.58%	508.76%
INVESTING ACTIVITIES
Capital Expenditures	$32.84M	$11.26M	$7.380M
YoY Change	3431.29%	2580.95%	3414.29%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$32.84M	-$11.26M	-$7.380M
YoY Change		-95.1%	3414.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	117.7M	118.6M	-$455.0K
YoY Change		-48.88%	-112.78%
NET CHANGE
Cash From Operating Activities	-25.40M	-5.690M	-492.6K
Cash From Investing Activities	-32.84M	-11.26M	-$7.380M
Cash From Financing Activities	117.7M	118.6M	-$455.0K
Net Change In Cash	59.44M	101.7M	-492.6K
YoY Change	-53003.1%	9168.93%
FREE CASH FLOW
Cash From Operating Activities	-$25.40M	-$5.690M	-$492.6K
Capital Expenditures	$32.84M	$11.26M	$7.380M
Free Cash Flow	-$58.24M	-$16.95M	-$7.873M
YoY Change	5487.22%	1151.22%	3648.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001854270
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays	P20D
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40440
	dei	Entity Registrant Name EntityRegistrantName	Senti Biosciences, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2437900
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Corporate Drive, First Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	(650)
	dei	Local Phone Number LocalPhoneNumber	239-2030
	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	SNTI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43386900	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	139800000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56034000	usd
CY2022Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	573000	usd
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	483000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3546000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3676000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	143919000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	60193000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3257000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3257000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35505000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12368000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19474000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20708000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	207000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	176000	usd
CY2022Q2	us-gaap	Assets Assets	202362000	usd
CY2021Q4	us-gaap	Assets Assets	96702000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5755000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5187000	usd
CY2022Q2	snti	Early Exercise Liability Current EarlyExerciseLiabilityCurrent	297000	usd
CY2021Q4	snti	Early Exercise Liability Current EarlyExerciseLiabilityCurrent	626000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	833000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1656000	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9056000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	5331000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1857000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1743000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	17798000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14543000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29018000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20988000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	810000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	usd
CY2022Q2	snti	Early Exercise Liability Noncurrent EarlyExerciseLiabilityNoncurrent	470000	usd
CY2021Q4	snti	Early Exercise Liability Noncurrent EarlyExerciseLiabilityNoncurrent	619000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	176000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	48096000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	36326000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	19517990	shares
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	19517988	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	19517988	shares
CY2022Q2	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	usd
CY2021Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	163800000	usd
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	171833000	usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	292698000	usd
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	27006600	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43368270	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43368270	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2972409	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2972409	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3619000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-138436000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115076000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	154266000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-111457000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	202362000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	96702000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1108000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	778000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1962000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	822000	usd
CY2022Q2	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	250000	usd
CY2021Q2	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	15000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	500000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	43000	usd
CY2022Q2	us-gaap	Revenues Revenues	1358000	usd
CY2021Q2	us-gaap	Revenues Revenues	793000	usd
	us-gaap	Revenues Revenues	2462000	usd
	us-gaap	Revenues Revenues	865000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9247000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5235000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16849000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10138000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13882000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4554000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19141000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8865000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	23129000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	9789000	usd
	us-gaap	Operating Expenses OperatingExpenses	35990000	usd
	us-gaap	Operating Expenses OperatingExpenses	19003000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-21771000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8996000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-33528000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18138000	usd
CY2022Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	27000	usd
CY2021Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	31000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-8878000	usd
CY2021Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-8878000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1289000	usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1289000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q2	snti	Fair Value Adjustment Preferred Stock Tranche Liability FairValueAdjustmentPreferredStockTrancheLiability	0	usd
CY2021Q2	snti	Fair Value Adjustment Preferred Stock Tranche Liability FairValueAdjustmentPreferredStockTrancheLiability	2918000	usd
	snti	Fair Value Adjustment Preferred Stock Tranche Liability FairValueAdjustmentPreferredStockTrancheLiability	0	usd
	snti	Fair Value Adjustment Preferred Stock Tranche Liability FairValueAdjustmentPreferredStockTrancheLiability	14742000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-95000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-30000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-131000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10219000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3011000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10168000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-14871000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-11552000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11552000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12007000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12007000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23360000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23360000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33009000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33009000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.86
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.86
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.13
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.80
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.80
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-11.45
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.45
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13446622	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13446622	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2909105	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2909105	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8336451	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8336451	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2883582	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2883582	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11536136	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	89662000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-58713000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	6000	usd
CY2021Q1	snti	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	277977	shares
CY2021Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	2294000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1432000	usd
CY2021Q1	snti	Early Exercise Of Stock Options Value EarlyExerciseOfStockOptionsValue	1329000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	372000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-21002000	usd
CY2021Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11814113	shares
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	91956000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-79240000	usd
CY2021Q2	snti	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	7703875	shares
CY2021Q2	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	79877000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21000	usd
CY2021Q2	snti	Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions	28000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	562000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12007000	usd
CY2021Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	19517988	shares
CY2021Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	171833000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-90636000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	19517988	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	171833000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-111457000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	422000	usd
CY2022Q1	snti	Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions	375000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	661000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-11808000	usd
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	19517988	shares
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	171833000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-121807000	usd
CY2022Q2	snti	Temporary Equity Shares Conversion Of Convertible Securities TemporaryEquitySharesConversionOfConvertibleSecurities	19517988	shares
CY2022Q2	snti	Temporary Equity Value Conversion Of Convertible Securities TemporaryEquityValueConversionOfConvertibleSecurities	-171833000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	171835000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	112182000	usd
CY2022Q2	snti	Adjustments To Additional Paid In Capital Contingent Consideration Liability On Closing Of The Reverse Recapitalization AdjustmentsToAdditionalPaidInCapitalContingentConsiderationLiabilityOnClosingOfTheReverseRecapitalization	9688000	usd
CY2022Q2	snti	Stock Issued During Period Value Cancellation And Exchange Of Convertible Debt StockIssuedDuringPeriodValueCancellationAndExchangeOfConvertibleDebt	5184000	usd
CY2022Q2	snti	Adjustments To Additional Paid In Capital Gain On Embedded Derivative AdjustmentsToAdditionalPaidInCapitalGainOnEmbeddedDerivative	-1289000	usd
CY2022Q2	snti	Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions	102000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9225000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	74000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-11552000	usd
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	154266000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23360000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33009000	usd
	us-gaap	Depreciation Depreciation	512000	usd
	us-gaap	Depreciation Depreciation	347000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1433000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	757000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1289000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-8878000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
	snti	Fair Value Adjustment Preferred Stock Tranche Liability FairValueAdjustmentPreferredStockTrancheLiability	0	usd
	snti	Fair Value Adjustment Preferred Stock Tranche Liability FairValueAdjustmentPreferredStockTrancheLiability	14742000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9886000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	934000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-13000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	8000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	90000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	345000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1372000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	779000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	234000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	910000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	203000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	649000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-999000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2663000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	7945000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-728000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15754000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13859000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18640000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	626000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18640000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-626000	usd
	snti	Proceeds From Merger And Related Pipe Financing Net Of Transaction Costs ProceedsFromMergerAndRelatedPIPEFinancingNetOfTransactionCosts	112464000	usd
	snti	Proceeds From Merger And Related Pipe Financing Net Of Transaction Costs ProceedsFromMergerAndRelatedPIPEFinancingNetOfTransactionCosts	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	521000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1453000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5175000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	66952000	usd
	snti	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	0	usd
	snti	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	480000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	118160000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	67925000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	83766000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	53440000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59291000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31034000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143057000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84474000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	139800000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82942000	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	3257000	usd
CY2021Q2	us-gaap	Restricted Cash RestrictedCash	1532000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143057000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84474000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9371000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	427000	usd
	snti	Recognition Of Preferred Stock Tranche Liability RecognitionOfPreferredStockTrancheLiability	0	usd
	snti	Recognition Of Preferred Stock Tranche Liability RecognitionOfPreferredStockTrancheLiability	33000	usd
	snti	Extinguishment Of Preferred Stock Tranche Liability ExtinguishmentOfPreferredStockTrancheLiability	0	usd
	snti	Extinguishment Of Preferred Stock Tranche Liability ExtinguishmentOfPreferredStockTrancheLiability	15210000	usd
	snti	Merger And Related Pipe Financing Costs Incurred But Not Yet Paid MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid	263000	usd
	snti	Merger And Related Pipe Financing Costs Incurred But Not Yet Paid MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid	0	usd
	snti	Deferred Transaction Costs Related To Pending Business Combination In Accounts Payable And Accrued Expenses DeferredTransactionCostsRelatedToPendingBusinessCombinationInAccountsPayableAndAccruedExpenses	0	usd
	snti	Deferred Transaction Costs Related To Pending Business Combination In Accounts Payable And Accrued Expenses DeferredTransactionCostsRelatedToPendingBusinessCombinationInAccountsPayableAndAccruedExpenses	1161000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-138400000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115100000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23400000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33000000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143100000	usd
	snti	Number Of Business Activities NumberOfBusinessActivities	1	businessactivitiy
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	reportablesegment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the valuation of stock-based awards, the accrual for research and development expenses, the valuation of contingent earnout, the valuation of convertible notes, the valuation of common and redeemable convertible preferred stock, the valuation of preferred stock tranche liability, standalone selling price (“SSP”) and the determination of the incremental borrowing rate. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div>
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares ReverseRecapitalizationContingentConsiderationEquityShares	2000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Number Of Tranches ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches	2	tranche
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares Per Tranche ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche	1000000	shares
CY2022Q2	snti	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.1957
CY2022Q2	snti	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.1957
CY2022Q2	snti	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.1957
CY2022Q2	snti	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.1957
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares ReverseRecapitalizationContingentConsiderationEquityShares	2000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Number Of Tranches ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches	2	tranche
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares Per Tranche ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche	1000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays	P20D
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Consecutive Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays	P30D
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	1157000	usd
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Threshold Of Years For Change Of Control ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl	P3Y
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5060000	shares
CY2022Q2	snti	Stock Converted Reverse Recapitalization StockConvertedReverseRecapitalization	23163614	shares
CY2022Q2	snti	Early Exercised Shares Subject To Repurchase EarlyExercisedSharesSubjectToRepurchase	288807	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43368270	shares
CY2022Q2	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	19517988	shares
CY2022Q2	snti	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	140700000	usd
CY2022Q2	snti	Reverse Recapitalization Transaction Costs ReverseRecapitalizationTransactionCosts	23300000	usd
	snti	Reverse Recapitalization Accrued Transaction Costs ReverseRecapitalizationAccruedTransactionCosts	300000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143057000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143057000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59291000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59291000	usd
CY2022Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	143057000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	810000	usd
CY2022Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	810000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	59291000	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2535000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	798000	usd
CY2022Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	983000	usd
CY2022Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1446000	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	28000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	275000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3546000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3676000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	37623000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14023000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2118000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1655000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35505000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12368000	usd
	us-gaap	Depreciation Depreciation	500000	usd
	us-gaap	Depreciation Depreciation	300000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	300000	usd
CY2021Q2	us-gaap	Depreciation Depreciation	200000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7234000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2555000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1799000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2665000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	23000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	111000	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9056000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	5331000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1325000	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	679000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	2650000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1359000	usd
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	27000	usd
CY2021Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	30000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	182000	usd
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	161000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	353000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	404000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	1534000	usd
CY2021Q2	us-gaap	Lease Cost LeaseCost	840000	usd
	us-gaap	Lease Cost LeaseCost	3033000	usd
	us-gaap	Lease Cost LeaseCost	1763000	usd
	snti	Operating Lease Proceeds Payments OperatingLeaseProceedsPayments	6740000	usd
	snti	Operating Lease Proceeds Payments OperatingLeaseProceedsPayments	-1320000	usd
	snti	Remeasurement Of Rou And Lease Liabilities Due To Changes In The Timing Of Receipt Of Lease Incentives RemeasurementOfROUAndLeaseLiabilitiesDueToChangesInTheTimingOfReceiptOfLeaseIncentives	199000	usd
	snti	Remeasurement Of Rou And Lease Liabilities Due To Changes In The Timing Of Receipt Of Lease Incentives RemeasurementOfROUAndLeaseLiabilitiesDueToChangesInTheTimingOfReceiptOfLeaseIncentives	0	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y2M12D
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y9M18D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.091
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1394000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6272000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7265000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7489000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7723000	usd
CY2022Q2	snti	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	30230000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	60373000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	20137000	usd
CY2022Q2	snti	Tenet Improvement Reimbursements TenetImprovementReimbursements	9361000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	30875000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	19517990	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	19517988	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	19517988	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	171833000	usd
CY2021Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	163834000	usd
CY2022Q2	snti	Temporary Equity Conversion Ratio TemporaryEquityConversionRatio	1
CY2022Q2	snti	Number Of Votes Per Common Share NumberOfVotesPerCommonShare	1	vote
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	27006600	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11560910	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	23000816	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares ReverseRecapitalizationContingentConsiderationEquityShares	2000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Number Of Tranches ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches	2	tranche
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares Per Tranche ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche	1000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Consecutive Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays	P30D
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Threshold Of Years For Change Of Control ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl	P3Y
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Fair Value ReverseRecapitalizationContingentConsiderationFairValue	9800000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9700000	usd
CY2022Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	100000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-8900000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-8900000	usd
CY2019Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	300000	usd
CY2019Q2	snti	Revenue Remaining Performance Obligation Variable Consideration Amount RevenueRemainingPerformanceObligationVariableConsiderationAmount	300000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Modification Of Contract ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract	-300000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	500000	usd
CY2021Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	300000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1000000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	300000	usd
CY2021Q2	us-gaap	Contract With Customer Asset Gross ContractWithCustomerAssetGross	0	usd
CY2022Q2	us-gaap	Contract With Customer Asset Gross ContractWithCustomerAssetGross	0	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2291838	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.39
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11304000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	199807	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.49
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	424485	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.77
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1667546	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.02
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.80
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	9000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	421763	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.60
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M18D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	9000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9225000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	562000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9886000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	934000	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	32100000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M3D
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9200000	usd
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M6D
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-11552000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12007000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-23360000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33009000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13446622	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13446622	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2909105	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2909105	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8336451	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8336451	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2883582	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2883582	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.86
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.86
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.13
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.80
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-11.45
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.45
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	46000000	usd
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11068175	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11068175	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21832990	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21832990	shares
CY2021Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P11Y
	snti	Collaborative Arrangement Rights And Obligations Contractual Annual Payments CollaborativeArrangementRightsAndObligationsContractualAnnualPayments	100000	usd
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares ReverseRecapitalizationContingentConsiderationEquityShares	2000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Number Of Tranches ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches	2	tranche
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares Per Tranche ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche	1000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	snti	Number Of Seats On The Board Of Directors NumberOfSeatsOnTheBoardOfDirectors	7	tradingday
CY2022Q2	snti	Number Of Seats On The Board Of Directors NumberOfSeatsOnTheBoardOfDirectors	7	tradingday
CY2021Q4	snti	Number Of Seats On The Board Of Directors NumberOfSeatsOnTheBoardOfDirectors	7	tradingday

Files In Submission

Name	View Source	Status
0001854270-22-000019-index-headers.html	Edgar Link	pending
0001854270-22-000019-index.html	Edgar Link	pending
0001854270-22-000019.txt	Edgar Link	pending
0001854270-22-000019-xbrl.zip	Edgar Link	pending
a6302210qex103.htm	Edgar Link	pending
a6302210qex104.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
senti06302210qex311v2.htm	Edgar Link	pending
senti06302210qex312v2.htm	Edgar Link	pending
senti06302210qex321v2.htm	Edgar Link	pending
senti06302210qex322v2.htm	Edgar Link	pending
Show.js	Edgar Link	pending
snti-20220630.htm	Edgar Link	pending
snti-20220630.xsd	Edgar Link	pending
snti-20220630_cal.xml	Edgar Link	unprocessable
snti-20220630_def.xml	Edgar Link	unprocessable
snti-20220630_lab.xml	Edgar Link	unprocessable
snti-20220630_pre.xml	Edgar Link	unprocessable
snti-20220630_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SNTI
Senti Biosciences, Inc. Stock $snti

2022 Q3 Form 10-Q Financial Statement

#000185427022000019 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNTI Senti Biosciences, Inc. Stock $snti

2022 Q3 Form 10-Q Financial Statement

#000185427022000019 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNTI
Senti Biosciences, Inc. Stock $snti